287 related articles for article (PubMed ID: 34615371)
21. Novel hematological parameters for the evaluation of patients with myeloproliferative neoplasms: the immature platelet and reticulocyte fractions.
Strati P; Bose P; Lyle L; Gaw K; Zhou L; Pierce SA; Huynh-Lu J; Hirsch-Ginsberg CF; Bueso-Mendoza DE; Bueso-Ramos CE; Verstovsek S
Ann Hematol; 2017 May; 96(5):733-738. PubMed ID: 28247057
[TBL] [Abstract][Full Text] [Related]
22. Platelets in myeloproliferative neoplasms have a distinct transcript signature in the presence of marrow fibrosis.
Guo BB; Linden MD; Fuller KA; Phillips M; Mirzai B; Wilson L; Chuah H; Liang J; Howman R; Grove CS; Malherbe JA; Leahy MF; Allcock RJ; Erber WN
Br J Haematol; 2020 Jan; 188(2):272-282. PubMed ID: 31426129
[TBL] [Abstract][Full Text] [Related]
23. JAK-STAT signaling in the therapeutic landscape of myeloproliferative neoplasms.
O'Sullivan JM; Harrison CN
Mol Cell Endocrinol; 2017 Aug; 451():71-79. PubMed ID: 28167129
[TBL] [Abstract][Full Text] [Related]
24. Overview of Myeloproliferative Neoplasms: History, Pathogenesis, Diagnostic Criteria, and Complications.
Tremblay D; Yacoub A; Hoffman R
Hematol Oncol Clin North Am; 2021 Apr; 35(2):159-176. PubMed ID: 33641861
[TBL] [Abstract][Full Text] [Related]
25. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
Hobbs GS; Rozelle S; Mullally A
Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
[TBL] [Abstract][Full Text] [Related]
26. JAK2 inhibitors: are they the solution?
Santos FP; Verstovsek S
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1(0 1):S28-36. PubMed ID: 22035745
[TBL] [Abstract][Full Text] [Related]
27. Hemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasm.
Lamrani L; Lacout C; Ollivier V; Denis CV; Gardiner E; Ho Tin Noe B; Vainchenker W; Villeval JL; Jandrot-Perrus M
Blood; 2014 Aug; 124(7):1136-45. PubMed ID: 24951423
[TBL] [Abstract][Full Text] [Related]
28. Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?
Hasselbalch HC; Holmström MO
Semin Immunopathol; 2019 Jan; 41(1):5-19. PubMed ID: 30203226
[TBL] [Abstract][Full Text] [Related]
29. New Horizons in Myeloproliferative Neoplasms Treatment: A Review of Current and Future Therapeutic Options.
Penna D
Medicina (Kaunas); 2021 Oct; 57(11):. PubMed ID: 34833399
[TBL] [Abstract][Full Text] [Related]
30. Response to aspirin therapy in patients with myeloproliferative neoplasms depends on the platelet count.
Gremmel T; Gisslinger B; Gisslinger H; Panzer S
Transl Res; 2018 Oct; 200():35-42. PubMed ID: 30012347
[TBL] [Abstract][Full Text] [Related]
31. Accelerated Phase of Myeloproliferative Neoplasms.
Shahin OA; Chifotides HT; Bose P; Masarova L; Verstovsek S
Acta Haematol; 2021; 144(5):484-499. PubMed ID: 33882481
[TBL] [Abstract][Full Text] [Related]
32. Platelets in the myeloproliferative syndrome.
Weinfeld A; Branehög I; Kutti J
Clin Haematol; 1975 Jun; 4(2):373-92. PubMed ID: 1102193
[No Abstract] [Full Text] [Related]
33. Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors.
Helbig G
Med Oncol; 2018 Aug; 35(9):119. PubMed ID: 30074114
[TBL] [Abstract][Full Text] [Related]
34. Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm.
Pomicter AD; Eiring AM; Senina AV; Zabriskie MS; Marvin JE; Prchal JT; O'Hare T; Deininger MW
Exp Hematol; 2015 Jul; 43(7):537-45.e1-11. PubMed ID: 25912019
[TBL] [Abstract][Full Text] [Related]
35. Platelet biology and functions: new concepts and clinical perspectives.
van der Meijden PEJ; Heemskerk JWM
Nat Rev Cardiol; 2019 Mar; 16(3):166-179. PubMed ID: 30429532
[TBL] [Abstract][Full Text] [Related]
36. Are MPNs vascular diseases?
Finazzi G; De Stefano V; Barbui T
Curr Hematol Malig Rep; 2013 Dec; 8(4):307-16. PubMed ID: 24037420
[TBL] [Abstract][Full Text] [Related]
37. Platelet Signaling Pathways and New Inhibitors.
Grover SP; Bergmeier W; Mackman N
Arterioscler Thromb Vasc Biol; 2018 Apr; 38(4):e28-e35. PubMed ID: 29563117
[No Abstract] [Full Text] [Related]
38. Metabolic Vulnerabilities and Epigenetic Dysregulation in Myeloproliferative Neoplasms.
Sharma V; Wright KL; Epling-Burnette PK; Reuther GW
Front Immunol; 2020; 11():604142. PubMed ID: 33329600
[TBL] [Abstract][Full Text] [Related]
39. [Selected parameters of blood platelet function in patients with myeloproliferative syndrome].
Zuk E
Ann Acad Med Stetin; 1998; 44():137-54. PubMed ID: 9857536
[TBL] [Abstract][Full Text] [Related]
40. Changes in response to antiaggregatory treatment in patients with myeloproliferative neoplasms: a sequential study using multiple electrode aggregometry.
Robier C; Stettin M; Neubauer M
Blood Coagul Fibrinolysis; 2013 Dec; 24(8):869-73. PubMed ID: 24176950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
